Early menarche and childbirth accelerate aging-related outcomes and age-related diseases: Evidence for antagonistic pleiotropy in humans

Yifan Xiang[1], Vineeta Tanwar[1], Parminder Singh[1], Lizellen La Follette[1], Vikram Narayan[1], Pankaj Kapahi[1,2]*

Affiliations:

[1]The Buck Institute for Research on Aging, 8001 Redwood Blvd, Novato, CA 94945

[2]Department of Urology, University of California, San Francisco, 400 Parnassus Avenue, San Francisco, CA 94143

*Corresponding author: Pankaj Kapahi, Email: pkapahi@buckinstitute.org.

Abstract: Aging can be understood as a consequence of the declining force of natural selection with age. Consistent with this, the antagonistic pleiotropy theory of aging proposes that aging arises from trade-offs that favor early growth and reproduction. However, evidence supporting antagonistic pleiotropy in humans remains limited. Using Mendelian Randomization (MR), we demonstrated that later ages of menarche or first childbirth were genetically associated with longer parental lifespan, decreased frailty index, slower epigenetic aging, later menopause, and reduced facial aging. Moreover, later menarche or first childbirth were also genetically associated with a lower risk of several age-related diseases, including late-onset Alzheimer's disease (LOAD), type 2 diabetes, heart disease, essential hypertension, and chronic obstructive pulmonary disease (COPD). We validated the associations between the age of menarche, childbirth, and the number of childbirths with several age-related outcomes in the UK Biobank by conducting regression analysis of nearly 200,000 subjects. Our results demonstrated that menarche before the age 11 and childbirth before 21 significantly accelerated the risk of several diseases, and almost doubled the risk for diabetes, heart failure, and quadrupled the risk of obesity, supporting the antagonistic pleiotropy theory. We identified 158 significant single nucleotide polymorphisms (SNPs) that influenced age-related outcomes, some of which were involved in known longevity pathways, including IGF1, growth hormone, AMPK, and mTOR signaling. Our study also identified higher BMI as a mediating factor in causing the increased risk of certain diseases, such as type 2 diabetes and heart failure, in women with early menarche or early pregnancy, emphasizing the importance of the thrifty gene hypothesis in explaining in part the mechanisms behind antagonistic pleiotropy. Our study highlights the complex relationship between genetic legacies and modern diseases, emphasizing the need for gender-sensitive healthcare strategies that consider the unique connections between female reproductive health and aging.

Introduction

Given the decline in the force of natural selection with age, genes that influence aging and age-related diseases are likely to be selected for their influence on early life events [1]. The theory of antagonistic pleiotropy suggests that natural selection involves inherent trade-offs, where genes that are advantageous for early survival and reproduction may have detrimental effects later in life, contributing to the aging process and the development of age-related diseases [1-3]. Though evidence for antagonistic pleiotropy has been observed in invertebrate models, evidence for causal relationships in mammals, especially humans, is largely lacking [4]. The timing of reproductive events, such as menarche and childbirth, has long been recognized as a crucial aspect of human life history and evolution. However, accumulating evidence suggests that these reproductive milestones may have far-reaching implications [5,6].

Considering reproductive events are partly regulated by genetic factors that can manifest the physiological outcome later in life, we hypothesized that earlier or later onset of menarche and first childbirth could reflect broader genetic influences on longevity and disease susceptibility, serving as proxies for biological aging processes (**fig. S1** and **fig. S2**). Mendelian randomization (MR) is a term that applies to the use of genetic variation to address causal questions about how modifiable exposures influence different outcomes [7]. Two-sample and two-step MR analyses were adopted in our research to explore the genetic causal associations using the inverse variance weighted (IVW) model. We leveraged recent studies that have identified SNPs associated with early menarche or birth in humans, to examine their role in antagonistic pleiotropy. After preprocessing, there were 209 and 33 single nucleotide polymorphisms (SNPs) included in MR analyses for the two exposures, age at menarche [8] and age at first birth [9], respectively.

Later menarche was genetically associated with later aging outcomes

Since parental ages at death may reflect the genetic heritability of lifespan, parental ages at death were used as general aging outcomes [10]. Compared to early menarche, later age at menarche was significantly associated with later parental ages at death for mothers or fathers (Beta=2.27E-02, P=1.84×10^{-4}; Beta=1.97E-02, P=7.88×10^{-4} for father and mother's ages at death respectively) (**Fig. 1A** and **Table S1-S3**). Aging is the biggest risk factor for frailty and several age-related diseases. Later age at menarche was associated with a lower frailty index, which was calculated using a set of 49 self-reported questionnaire items on traits covering health, presence of diseases and disabilities, and mental well-being [11] (Beta=-2.36E-02, P=5.75×10^{-3}). After excluding the instrumental variables (IVs) associated with body mass index (BMI), the significant association between later menarche and outcomes remained based on the weighted median model (WMM) for frailty index (Beta=-2.88E-02, P=0.0202) and based on IVW for parental ages at death (Beta=1.47E-02, P=2.46×10^{-2}; Beta=1.24E-02, P=3.87×10^{-2}). Next, we examined the associations between the age of menarche and organ aging or age-related diseases (**Fig. 1A and 1B** and **Table S3**). Later age of menarche was associated with later menopause onset (Beta=1.16E-01, P=1.93×10^{-2}), lower risks of late-onset Alzheimer's disease (LOAD) (OR=0.897 (0.810–0.994), P=3.88×10^{-2}), chronic heart failure (CHF)

(OR=0.953 (0.913–0.995), P=2. 80×10^{-2}), essential hypertension (OR=0.966 (0.959–0.973), P=1.20×10^{-22}),

facial aging (Beta=-1.76E-02, P=2.16×10^{-9}), and early onset chronic obstructive pulmonary disease (COPD)

(OR=0.838 (0.755–0.931), P=9.50×10^{-4}) and mildly higher risk of osteoporosis (OR=1.009 (1.006–1.013),

P=1.95×10^{-7}). These associations were still significant after excluding SNPs associated with BMI, except

for CHF. One potential mechanism of antagonistic pleiotropy is accelerated cell growth and division;

therefore, we examined the relationship between menarche and certain cancers. Later age at menarche was

associated with lower risks of breast cancer (OR=0.859 (0.764–0.966), P=1.53×10^{-2}) and endometrial cancer

(OR=0.896 (0.840–0.956), P=9.02×10^{-4}) compared with early menarche (**Fig. 1B**).

Later age at first birth was genetically associated with later aging outcomes

Next, we examined the associations between the age of childbirth and age-related outcomes. Compared to

early first birth, later age at first birth was associated with lower frailty index (Beta=-6.48E-02, P=5.93×10^{-11})

and GrimAge, a measure of epigenetic aging (Beta=2.67E-01, P=4.37×10^{-2}), and older parental ages at

death (Beta=3.43E-02, P=6.88×10^{-5} for father's age at death; Beta=3.37E-02, P=1.78×10^{-4} for mother's age

at death) (**Fig. 1A**). Similar to results with the age of menarche, later age at first birth was associated with

later menopause onset (Beta=2.67E-01, P=3.08×10^{-4}), lower risks of type 2 diabetes (OR=0.890 (0.847–

0.935), P=3.65×10^{-6}), CHF (OR=0.926 (0.866–0.991), P=2.56×10^{-2}), essential hypertension (OR=0.966

(0.957–0.974), P=3.45×10^{-15}), and gastrointestinal or abdominal disease (GAD) (OR=0.975 (0.965–0.985),

P=2.02×10^{-6}). Most significant associations remained after the BMI-related SNPs were excluded, except for

CHF (**Fig. 1A and 1C** and **Table S3**). Furthermore, later age at first birth was also significantly associated

with a lower risk of cervical cancer (OR=0.978 (0.975–0.982), P=8.67×10^{-38}) but not breast and endometrial

cancers (**Fig. 1C**).

BMI is an important mediator in significant associations

As BMI is an important modulator of aging [12], we examined its role in explaining these associations. Based

on the two-sample MR analyses, significant associations between early menarche and CHF, and between

early first birth and CHF and cervical cancer, were not observed after excluding SNPs related to BMI (**Fig.**

1). To estimate the effect of BMI as the mediator, we further conducted two-step MR. Exposures of age of

menarche and age at first birth, and outcomes of frailty index, type 2 diabetes, and CHF, were included in

the two-step MR analysis. Later ages of menarche and first birth were associated with lower BMI (Beta=-

5.36E-02, P=2.73×10^{-13}; Beta=-4.49E-02, P=6.85×10^{-5}). Higher BMI was associated with higher risks of

type 2 diabetes (OR=2.391 (2.243–2.550), P=4.65×10^{-156}), CHF (OR=1.690 (1.570–1.819), P=1.67×10^{-44}),

and cervical cancer (OR= 1.019 (1.005–1.033), P=8.18×10^{-3}). Significant pleiotropy was detected in the

association between BMI and frailty index. Two-step MR showed that BMI significantly mediated the

associations between menarche and, type 2 diabetes or CHF (**Table S4**). BMI also significantly mediated the

associations between first birth and, type 2 diabetes, CHF, or cervical cancer (**Table S4**). As both early

menarche and first birth were associated with higher BMI, the BMI had a significant effect to explain the

associations partially. Results of colocalization analysis showed 5 SNPs associated with both the exposures and outcomes (**Table S5**). The genetic correlation results analyzed with LDSC method are listed in Table S6.

Mechanisms explaining antagonistic pleiotropy We identified 158 significant SNPs in the genes from the MR analysis for their association between age of menarche or first birth with 15 aging and age-related disease outcomes. These SNPs were then listed according to (i) the number of study outcomes they were associated with and (ii) their frequency of occurrence in the European and global population. We chose to depict only the SNPs that were associated with greater than three outcomes as shown in **Fig. 2**. The SNP rs2003476 in the *CRTC1* gene was found to be associated with seven aging and age-related disease outcomes (frailty index, LOAD, CHF, father's age at death, mother's age at death, breast, and endometrial cancer). Previous studies have indicated that CRTC1 transcription domain is linked with extending the lifespan in C. elegans [13] and a decrease in CRTC1 levels was found to be associated with human AD [14]. Two other genes involved in the glutathione metabolism pathway, *CHAC1* and *GGT7*, were also found to be associated with four different aging outcomes (*CHAC1* was associated with frailty index, diabetes, COPD, and BMI; *GGT7* was associated with father's age at death, endometrial cancer and BMI) (**Fig. 2**). Importantly, the SNP in *CHAC1* is a missense variant, suggesting its impact on protein translation and potential contribution to disease biology. CHAC1 has recently been implicated in age-related macular degeneration [15] and muscle wasting [16]. Posttranslational protein-lipid modification processes are known to contribute to aging and age-related diseases [17]. N-myristoylation is one such process that is catalyzed by NMT (N-myristoyltransferase) [18], another intriguing gene candidate identified in our analysis. We found an association of *NMT1* with four aging outcomes: T2D, CHF, essential hypertension, and breast cancer. Various myristoylated proteins have been implicated in diverse intracellular signaling pathways [19] including AMP-activated protein kinase (AMPK) [20,21]. It has been shown that NMT1 exerts synovial tissue-protective functions by promoting the recruitment of AMPK to lysosomes and inhibiting mTORC1 signaling [20]. In addition, drugs targeting NMTs (NMT1 and NMT2) have been suggested to be potent senolytics [22] and a target for treating or preventing various diseases such as cancer [23,24] and heart failure [25]. Furthermore, modulating the evolutionarily conserved N-myristoyl transferase NMT1 was shown to extend lifespan in yeast [26]. The full table of SNPs and their population frequency and association with aging outcomes is provided in **Table S7**.

Canonical signaling pathways analysis. A total of 563 canonical signaling pathways related to 158 SNPs/gene outcomes were identified based on the Ingenuity Pathway Knowledge Base (IPKB). After ranking the identified canonical signaling pathways according to their adjusted P-values, the top 25 canonical signaling pathways with a p-value $< 10^{-2}$ enriched by SNPs/genes involved in the age of menarche and first birth are represented in **Fig. 3A**. The top enriched canonical signaling pathways fell into these broader categories: (1) Developmental and cellular signaling pathways, such as BMP, IGF-1, and growth hormone signaling, and signaling by Activin; (2) Neuronal signaling and neurological disorders, including glioma signaling, amyloid processing, activation of NMDA receptors and postsynaptic events, and

neuropathic pain signaling; (3) Metabolic and endocrine signaling pathways, such as mTOR signaling, leptin signaling, PFKFB4 signaling, and melatonin signaling; (4) Immunological and inflammatory pathways, which include lymphotoxin β receptor and IL-22 signaling; (5) Cardiovascular and muscular signaling pathways, including the role of NFAT in cardiac hypertrophy. In addition to canonical pathways, SNPs/genes were shown to be further associated with diseases and functions. IPA showed a total of 78 diseases and functions associated with age at menarche and first birth. These associated diseases and functions were rated according to their adjusted P-values, and the top 20 enriched categories with a P-value $< 10^{-5}$ were selected and depicted in **Fig. 3B**.

Gene network analysis and drug interactions. Besides pathway and disease associations, the 158 SNPs/genes were further connected to identify 12 functional networks using IPA. These IPA networks were ranked based on their consistency scores. The top 5 networks included a range of 13-22 genes with scores above 25, indicating robust regulatory analysis [27] (**Table S8**). The top networks were mainly connected to the following functions: cancer, hematological disease, immunological disease (**Fig. 3C**), cardiovascular disease, organismal injury and abnormalities, reproductive system development and function (**Fig. 3D**), and cell-to-cell signaling and interaction. These results support the notion that dynamic cellular interactions and the development of various vital organ systems influenced by age at menarche and first birth also influence age-related diseases. The two top IPA networks were further outlined in **Fig. 3C** and **3D**. To further explore the drugs targeting genes associated with age at menarche and first birth, we conducted an analysis using ChEMBL[28] and DrugBank databases[29]. This examination revealed that a total of 11 FDA-approved drugs target the identified genes (*PRKAG2, SCN2A, DPYD, MC3R, AKT, MAPK, KCNK9, TACR3, HTR4, RXRG*) (**Table S9**).

Population validation for associations between age at menarche, or first live birth, or number of births with age-related outcomes

Next, we validated the genetic associations in the population cohort of the UK Biobank. 264,335, 184,481, and 259,758 participants were included for independent variables of age at menarche, age at first live birth, and number of births, respectively (**Table S10**). Ages at menarche were divided into 5 age groups, <11y, 11-12y, 13-14y, 15-16y, and >16y. The probability of living to 80 years old, having menopause ≥50 years old, risk of diabetes, high blood pressure (HBP), heart failure, COPD, breast cancer, endometrial cancer, and obesity were compared among the 5 age groups of menarche. Each of the outcomes was compared between the highest and lowest education levels and 3 BMI categories (18.5-24.9, 25-29.9, and ≥30) among the 5 age groups (**Fig. 4A-I**). The ORs for each age group were calculated based on the coefficients (β) in logistic regression after including confounders of smoking, alcohol, education, and BMI. Compared to the group with menarche under 11 years old, which generally had the highest risk, females with menarche at 13-14y had the highest probability of living to 80 years old (OR=1.412, P<0.001) and having menopause ≥50 years

old (OR=1.146, P<0.001), and had the lowest risk of diabetes (OR=0.773, P<0.001), heart failure (OR=0.835, P<0.001), and COPD (OR=0.728, P<0.001). The group with menarche at 15-16y had the lowest risks of high blood pressure (HBP) (OR=0.793, P<0.001) and obesity (OR=0.337, P<0.001). Females with menarche >16y had the lowest risks of breast cancer (OR=0.832, P<0.05) and endometrial cancer (OR=0.641, P<0.05) compared to females with menarche <11y (**Table S11**).

Ages at first birth were divided into 5 age groups, <21y, 21-25y, 26-30y, 31-35y, and >35y. The probability of living to 80 years old, having menopause ≥50 years old, risk of diabetes, AD, HBP, heart failure, cerebral infarction, digestive system disease, cervical cancer, and obesity were compared among the 5 age groups of first live birth. Compared to the group with first live birth under 21 years old, which generally had the highest risks, females with first live birth at 21-25y had the highest probability to live to 80 years old (OR=1.667, P<0.001), and females with first live birth at 26-30y had the highest probability to have menopause ≥50 years old (OR=1.184, P<0.001) and lowest risk of cervical cancer (OR=0.587, P<0.01).

Females with first live birth at 31-35y had the lowest risk of diabetes (OR=0.612, P<0.001). Females with first live birth >35y had the lowest risk of having AD (OR=0.474, P<0.01), HBP (OR=0.587, P<0.001), heart failure (OR=0.446, P<0.001), cerebral infarction (OR=0.485, P<0.001), digestive system disease (OR=0.569, P<0.001), and obesity (OR=0.416, P<0.001) (**Fig. 4J-S**).

Females with the number of births from 0 to 4 were included. Compared to no birth, females with 3 births had the highest probability of living to 80 years old (OR=1.818, P<0.001) and having menopause ≥50 years old (OR=1.562, P<0.001). Females with 4 births had the highest risk of diabetes (OR=1.399, P<0.001), AD (OR=1.676, P<0.001), HBP (OR=1.274, P<0.001), heart failure (OR=1.439, P<0.001), cerebral infarction (OR=1.470, P<0.001), digestive system disease (OR=1.370, P<0.001), and obesity (OR=1.327, P<0.001) but lowest risk of breast cancer (OR=0.869, P<0.001) (**Fig. 4T-AC**). The significant estimated effect (β) of each group compared to the youngest age groups of menarche and first live birth and 0 birth group and the ability to explain the variability of outcomes in regression analysis are exhibited in **Table S11**.

To estimate the combined effect of age at menarche and first live birth on diabetes, HBP, heart failure, and BMI≥30, participants were divided into 25 groups according to the menarche and first live birth ages. Females with menarche<11y and first live birth<21y had higher risks of diabetes (OR=1.881, P<0.001), HBP (OR= 1.436, P<0.05), heart failure (OR= 1.776, P<0.01), and BMI≥30 (OR= 4.417, P<0.001) compared to females with menarche of 13-14y and first live birth of 26-30y (**Table S12** and **fig. S3**).

Discussion

The timing of reproductive milestones such as the age of menarche and age at first birth is partly governed by genetic factors, which may exert lasting impacts on an individual's health trajectory. Our study finds

support for antagonistic pleiotropy by demonstrating that genetic variants that drive early menarche or early pregnancy accelerate several aging outcomes, including parental age, frailty index, and several age-related diseases such as diabetes and dementia. These results were validated in a cohort from the UK biobank, showing that women with early menarche, or early pregnancy were associated with accelerated aging outcomes and increased risk of several age-related diseases. These results are also consistent with the disposable soma theory that suggests aging as an outcome tradeoff between an organism's investment in reproduction and somatic maintenance and repair. Both antagonistic pleiotropy theory and the disposable soma theory provide valuable evolutionary frameworks for interpreting how reproductive traits influence long-term health, yet they emphasize distinct biological mechanisms. Antagonistic pleiotropy [2] highlights the temporal trade-off of gene function, proposing that alleles promoting fertility or reproductive success early in life may have detrimental effects in later life. In contrast, the disposable soma theory [30,31] emphasizes a resource allocation trade-off, where investment in reproduction occurs at the cost of somatic maintenance and repair, ultimately accelerating aging and increasing susceptibility to disease. Future research could aim to explore these mechanisms by integrating genetic, metabolic, and longitudinal data, which help understand the interaction between gene-driven effects and resource-driven physiological trade-offs.

Consistent with a recent study suggesting the relation of early first birth with a higher likelihood of frailty [32], our MR analysis provided a strong association between early age of first birth and GrimAge, a DNA methylation based marker to predict epigenetic age. Our findings align with the observed negative genetic correlation between reproductive traits and lifespan that individuals with higher polygenetic scores for reproduction have lower survivorships to age 76 [33]. Prior studies linking the female reproductive factors with aging are either limited to results obtained from observational studies [34,35] or are limited to few outcomes such as brain disorders [36,37]. Besides, emerging evidence suggests that early puberty in males is linked to adverse health outcomes, such as an increased risk of cardiovascular disease, type 2 diabetes, and hypertension in later life [38]. A Mendelian randomization study also reported a genetic association between the timing of male puberty and reduced lifespan [39]. These findings support the hypothesis that genetic variants associated with delayed reproductive timing in males might similarly confer health benefits or improved longevity, akin to the patterns observed in females. This would suggest that similar mechanisms of antagonistic pleiotropy could operate in males as well.

Using MR, we identified 158 SNPs associated with early menarche or first birth that significantly influence age-related outcomes. Among the top 25 enriched canonical signaling pathways, those involved in developmental and cellular processes are particularly significant in determining the timing of menarche and first childbirth, with nearly one third of these pathways (8 out of 25) falling into this category. These developmental and cellular signaling pathways work together to regulate continuous growth and involution from puberty through menopause [40]. Interestingly, known longevity pathways such as insulin-like growth factor 1 (IGF1), growth hormone (GH) signaling, melatonin signaling, and bone morphogenetic protein

(BMP) signaling, seem to play a crucial role in regulating the timing of these reproductive events. IGF-1 signaling promotes the growth and development of reproductive organs and tissues [41-43], but is also a conserved modulator of longevity [44-47]. Melatonin, known for regulating circadian rhythms, influences the timing of menarche through its effects on the hypothalamic-pituitary-gonadal axis [48] and is postulated to modulate oxidative, inflammatory, and autophagy states [49]. Furthermore, different processes in early life such as cell proliferation or differentiation [50], ovarian function, and follicular development [51-53] are dependent on BMP signaling. However, increased BMP signaling also contributes significantly to AD pathology [54] and impairments in neurogenesis and cognitive decline associated with aging [55]. Aberrant BMP signaling is also shown to be associated with age-related metabolic and cardiovascular diseases [56,57]. Additionally, growth hormone signaling is not only vital for development during childhood and puberty [58] but also impacts longevity [59]. Besides signaling pathways, genes in age at menarche and first childbirth were connected in gene-gene interaction networks. IPA Network 1 revealed strong connections of our input genes to regulators involved in chromatin remodeling, immune signaling, and proteostasis. Notably, NF-κB, TGF-β, and IL-12—central players in inflammation and immune modulation—emerged as key hubs. While tightly regulated during early life to support immunity and tissue repair, chronic activation of these pathways is associated with inflammaging and immune dysfunction in later life [60,61]. Similarly, links to histone H3/H4 and modifiers like USP10 and USP49 suggest that dysregulation of chromatin and ubiquitin-mediated protein turnover may underlie both developmental gene expression programs and age-related epigenetic drift and proteotoxic stress [62,63]. The enrichment of E3 ligase-associated nodes (e.g., E3:K48-ubiquitinated substrate, ubiquitin) further supports a central role for proteostasis networks in aging [62,64]. These associations reflect the principle of antagonistic pleiotropy—where genes and pathways essential for early-life growth, stress resilience, and immune function become liabilities later in life, contributing to aging and age-related diseases [65]. In IPA network 2, most genes were connected with either *AKT* or genes encoding for follicle-stimulating hormone (*FSH*), luteinizing hormone (*LH*), leptin receptor (*LEPR*), and inhibin subunit beta A (*INHBA*). AKT signaling is implicated in oocyte maturation and embryonic development [66] and mediates pregnancy-induced cardiac adaptive responses [67]. AKT signaling also mediates age-related disease pathologies, such as AD[68]. Major ovarian functions are controlled by FSH (follicular growth, cellular proliferation, and estrogen production) and LH (oocyte maturation, ovulation, and terminal differentiation of follicles) which in turn are modulated by other ovarian factors such as INHBA (a subunit of activin and inhibin) [69,70]. Endocrine alterations at advanced aging or reproductive aging [71] are marked by changes in FSH and LH due to altered feedback resulting from the ovarian decline in sex steroids, inhibin A, and inhibin B production [72-74]. These studies underscore the importance of considering that dysregulation or abnormal activation of any of these pathways could contribute to the onset of late-life diseases consistent with antagonistic pleiotropy in humans [2,75].

The thrifty gene hypothesis provides a compelling framework to explain antagonistic pleiotropy, particularly in the context of modern health challenges. The thrifty gene hypothesis suggests that genes favoring efficient energy storage were advantageous in historical periods of food scarcity, helping individuals survive through

famines. However, in today's environment of abundant food, the same genes contribute to obesity and metabolic diseases like diabetes. Similarly, in the context of antagonistic pleiotropy, we hypothesize that genes that enhance early-life reproductive success favor efficient energy storage to support reproductive health. This is supported by our observation that early pregnancy is associated with increasing BMI, a recognized key factor in systemic aging [76,77]. In support of this, we found a lack of significant association between early menarche or age at first birth for CHF and cervical cancer after removal of BMI as a confounder in MR analysis. Based on regression analysis at the population level (Fig. 4), higher BMI was associated with higher risks of cardiovascular diseases and diabetes. Thus, an increase in BMI is one of the factors that explains the increased risk of age-related disease seen due to the exposure of early pregnancy or the prevalence of genes that enhance early reproductive success. These results are also consistent with calorie restriction being a robust way to extend healthspan and lifespan in many species [78].

Several limitations of our study need to be considered. Firstly, all the associations are explored at the genetic level with MR and population level with the UK Biobank. However, to confirm causal relationships, further validation through *in vitro* and *in vivo* research is essential. Secondly, though we excluded confounder-related SNPs and addressed potential pleiotropic effects, there may also be potential bias which could be addressed by extending these findings to other populations. Thirdly, significant heterogeneity and pleiotropy remained in some association analyses, which need further exploration. Fourthly, research regarding male-specific reproductive traits and their relationship to aging and health outcomes is needed to compare the difference between male and female aging. Given the increasing age of first childbirth in modern times, the ideal period of first childbirth for both slowing down female aging and benefiting fetal development needs more research [79]. In summary, our study underscores the complex relationship between genetic legacies and modern diseases. Understanding these genetic predispositions can inform public health strategies and their relevance to age-related disease outcomes in women of various ethnic groups. For example, interventions could be tailored not only to mitigate the risks associated with early reproductive timing but also to address lifestyle factors exacerbating conditions linked to thrifty genes, like diet and physical activity.

Methods

All the MR research data is from the public genome-wide association studies (GWAS) databases of the IEU Open GWAS project (https://gwas.mrcieu.ac.uk/) and PubMed. The target analysis is based on public datasets. The population data is from the UK Biobank. No definite personal information was included. No additional ethical approval was required for our study.

Exposure data

2 traits were included as female reproductive activity exposures, involving age at menarche [8] (GWAS ID: ebi-a-GCST90029036) and age at first birth [9] (GWAS ID: ebi-a-GCST90000048).

Outcome data

The aging outcomes involved general aging, organ aging/disease, and organ cancers (Table S1). Frailty index [80] (GWAS ID: ebi-a-GCST90020053), father's age at death[81] (GWAS ID: ebi-a-GCST006700), mother's age at death [81] (GWAS ID: ebi-a-GCST006699), and DNA methylation GrimAge acceleration [82] (GWAS ID: ebi-a-GCST90014294) were included as general aging outcomes. Specific aging diseases and aging levels included age at menopause onset [8] (GWAS ID: ebi-a-GCST90029037), late-onset Alzheimer's disease [83] (LOAD) (PMID: 30820047), osteoporosis [84] (GWAS ID: ebi-a-GCST90038656), and type 2 diabetes [85] (GWAS ID: ebi-a-GCST90018926), chronic heart failure [85] (CHF) (GWAS ID: ebi-a-GCST90018806), essential hypertension (GWAS ID: ukb-b-12493), facial aging (GWAS ID: ukb-b-2148), eye aging [86] (PMID: 36975205), cirrhosis (GWAS ID: finn-b-CIRRHOSIS_BROAD), chronic kidney disease [87] (CKD) (GWAS ID: ebi-a-GCST008026), early onset chronic obstructive pulmonary disease (COPD) (GWAS ID: finn-b-COPD_EARLY), and gastrointestinal or abdominal disease (GAD) [84] (GWAS ID: ebi-a-GCST90038597). Organ cancers included breast cancer [85] (GWAS ID: ebi-a-GCST90018799), ovarian cancer [85] (GWAS ID: ebi-a-GCST90018888), endometrial cancer [88] (GWAS ID: ebi-a-GCST006464), and cervical cancer (GWAS ID: ukb-b-8777).

SNPs selection

We identified single nucleotide polymorphisms (SNPs) associated with exposure datasets with $p < 5 \times 10^{-8}$ [89,90]. In this case, 249 SNPs and 67 SNPs were selected as eligible instrumental variables (IVs) for exposures of age at menarche and age at first birth, respectively. All selected SNPs for every exposure would be clumped to avoid the linkage disequilibrium ($r^2 = 0.001$ and $kb = 10,000$). Then we identified whether there were potential confounders of IVs associated with the outcomes based on a database of human genotype-phenotype associations, PhenoScanner V2 [91,92] (http://www.phenoscanner.medschl.cam.ac.uk/), with a threshold of $p < 1 \times 10^{-5}$. IVs associated with education, smoking, alcohol, activity, and other confounders related to outcomes would be excluded. During the harmonization process, we aligned the alleles to the human genome reference sequence and removed incompatible SNPs. Subsequent analyses were based on the merged exposure-outcome dataset. We calculated the F statistics to quantify the strength of IVs for each exposure with a threshold of $F>10$ [93]. If the effect allele frequency (EAF) was missing in the primary dataset, EAF would be collected from dsSNP (https://www.ncbi.nlm.nih.gov/snp/) based on the population to calculate the F value. As osteoporosis GWAS was processed by BOLT-LMM, we recalculated the beta value for MR analysis. To adjust the beta values (β_{BOLT}) estimated by BOLT-LMM for dichotomous, we applied the following formula to each SNP:

$$Adjusted\ beta = \frac{\beta_{BOLT}}{\sqrt{P(1 - P)}}$$

The prevalence (P) of the binary outcome in the population is the proportion of individuals with the outcomes. For example, the P value for osteoporosis was calculated based on the GWAS sample size (484,598) and disease cases (7,751). The adjusted beta values for essential hypertension, osteoporosis, GAD, and cervical cancer were calculated in MR analysis.

MR analysis

All analysis was performed using R software (version 4.3.1, R Foundation for Statistical Computing, Vienna, Austria) and RStudio software (version 2023.09.0 Posit, PBC, Boston, USA) with TwoSampleMR (version 0.5.7) and MRPRESSO (version 1.0) packages.

Five two-sample MR methods were applied for analysis, including inverse variance weighted model (IVW), MR Egger regression model (MER), weighted median model (WMM), simple mode, and weighted mode. A pleiotropy test was used to check if the IVs influence the outcome through pathways other than the exposure of interest. A heterogeneity test was applied to ensure whether there is a variation in the causal effect estimates across different IVs. Significant heterogeneity test results indicate that some instruments are invalid or that the causal effect varies depending on the IVs used. MRPRESSO was applied to detect and correct potential outliers of IVs with NbDistribution = 10,000 and threshold p = 0.05. Outliers would be excluded for repeated analysis. The causal estimates were given as odds ratios (ORs) and 95% confidence intervals (CI). A leave-one-out analysis was conducted to ensure the robustness of the results by sequentially excluding each IV and confirming the direction and statistical significance of the remaining SNPs.

In two-step MR, we mainly use IVW to access the causal associations between exposure and outcome, exposure and mediator, and mediator and outcome. Body mass index (BMI) (GWAS ID: ukb-b-19953) was applied as a mediator. Similar steps of two-sample MR were repeated in the analysis after excluding confounders. The mediator effect (ME) and direct effect (DE) were calculated. The MEs were calculated with the formula: beta1 × beta2; DEs were calculated according to the formula: beta – (beta1 × beta2), beta stands for the total effect obtained from the primary analysis, beta1 stands for the effect of exposure on the mediator, and beta2 stands for the effect of the mediator on the outcome.

Colocalization analysis

To improve the robustness of our research, colocalization analysis was conducted with packages gwasglue (version 0.0.0.9000), coloc (version 5.2.3), and gassocplot (version 1.0) between the exposures and outcomes revealing significant associations after BMI-related SNPs were excluded. SNPs with significant P values in single SNP OR analysis were set as target SNPs. SNP-level colocalization was conducted with 50kb [94] windows around each target SNP. EAF was set to 0.5 if it was missed in the primary datasets. The Bayesian algorithm in the coloc package generates posterior probabilities (PP) for the hypothesis that both traits are associated and share the same single causal variant at a specific lo[95,96]cus (H_4) [97]. SNP with significant results in the colocalization analysis would be removed and two-sample MR analyses would be conducted again.

Genetic correlation analysis

Genetic correlation analysis helps clarify whether there is a shared genetic architecture between two traits, which can support the interpretation of our MR results. LDSC software, a robust framework to estimate genetic correlation using GWAS summary statistics, was applied to calculate the genetic correlation [95,96].

GWAS summary statistics were filtered with HapMap3 ref. Variants, which were repeated or had a minor allele frequency (MAF) ≤0.01 were excluded. Genetic Correlation (r_g) was calculated for all pairwise comparisons among age at menarche, age at first birth, BMI, and age at menopause onset using LDSC method.

Target Analysis

We employed the Ingenuity Pathway Analysis (IPA) software (version 01-22-01; Ingenuity Systems; QIAGEN) to investigate various gene-related aspects associated with age at first birth and menarche. IPA is a widely used bioinformatics tool for interpreting high-throughput data [98]. Briefly, the SNPs/genes from MR analysis were uploaded into Qiagen's IPA system for core analysis and then the outcome was overlaid with the global molecular network in the Ingenuity pathway knowledge base (IPKB). IPA was performed to identify canonical pathways, diseases, and functions, and to investigate gene networks. Additionally, the Chemical Biology Database (ChEMBL) (https://www.ebi.ac.uk/chembl/), a large-scale database of bioactive molecules for drug discovery [28], and the DrugBank database [29], a comprehensive database on FDA-approved drugs, drug targets, mechanisms of action, and interactions (https://go.drugbank.com/), were used to identify candidate genes targeted by approved drugs in clinical trials or under current development phases.

Population validation

The MR results were further validated based on the UK Biobank with package stats (version 4.3.1). In addition to age at menarche and first live birth, the number of births is listed as an independent variable for the validation analysis. Based on the significant associations, regression analysis was adopted to explore the effect of independent variables and related confounders on outcomes. Ages at menarche were divided into 5 age groups, <11y, 11-12y, 13-14y, 15-16y, and >16y. Ages at first live birth were divided into 5 age groups, <21y, 21-25y, 26-30y, 31-35y, and >35y. Females with the number of births from 0 to 4 were included. Education was divided into 7 levels based on the degrees. Smoking was divided into 2 categories, ever smoking or not. Drinking was divided into 3 categories, never, previous, and current drinking. BMI was divided into four categories, <18.5, 18.5-24.9, 25-29.9, and ≥30 based on the average value of 4 records.

The outcome results were preprocessed based on the baseline information collection, follow-up outcome, surgical history, and ICD-10 diagnosis summary. Logistic regression was used for the analysis of disease risks (categorical variables). The coefficients (β) in logistic regression were log-odds ratios. Although the continuous variables exhibited mild to moderate skewed distributions, considering the large sample size, linear regression was used for the analysis of age at death, menopause age, and BMI in the first step. Then logistic regression was applied to confirm the robustness of the results with the outcome of death age ≥ 80, menopause age ≥ 50, and BMI ≥ 30. Confounders for regression analysis I include education, smoking, and drinking. Confounders for regression analysis II include education, smoking, drinking, and BMI. Variance Inflation Factors (VIF) were calculated for each predictor in regression analysis to avoid multicollinearity. Values of VIF were less than 1.5 for each predictor. For outcomes of diabetes, HBP, heart failure, and BMI≥

30, the combined effect of age at menarche and first birth was analyzed. 179,821 participants were divided into 25 groups according to the menarche and first live birth age groups. All other groups were compared to the group with menarche of "13-14y" and the first birth of "26-30y" in logistic regression (confounders including education, smoking, drinking, and BMI for diabetes, HBP, and heart failure; including education, smoking, and drinking for BMI≥30).

Data and code availability: All data and code are available in the main text, supplementary materials, or public resources. The population data is available through the UK Biobank.

Acknowledgments: We thank the Kapahi Lab at Buck Institute for helpful discussions. This research has been conducted using the UK Biobank Resource under Application Number 151101. **Funding:** Hevolution Foundation (PK). National Institute of Health grant R01AG068288 and R01AG045835 (PK). Larry L. Hillblom Foundation (PK), Larry L. Hillblom Foundation (PS). **Author contributions:** Conceptualization: YX, VT, PS, LLF, and PK. MR analysis and UK biobank validation: YX. Gene target analysis: VT. Funding acquisition: PK and PS. Writing original draft: YX, PS, and VT. All authors reviewed and edited the manuscript.

Competing interests: Authors declare that they have no competing interests.

Supplementary Materials

A Exposures and aging outcomes

Exposure	Outcome	BMI included	Beta		P value
Age at menarche	Frailty index	Y	-2.36e-02		5.75e-03
		N	-2.88e-02		2.02e-02
	Father's age at death	Y	2.27e-02		1.84e-04
		N	1.47e-02		2.46e-02
	Mother's age at death	Y	1.97e-02		7.88e-04
		N	1.24e-02		3.87e-02
	Age at menopause onset	Y	1.16e-01		1.93e-02
		N	1.15e-01		1.84e-02
	Facial aging	Y	-1.76e-02		2.16e-09
		N	-1.30e-02		1.97e-05
Age at first birth	Frailty index	Y	-6.49e-02		5.93e-11
		N	-5.20e-02		3.27e-06
	Father's age at death	Y	3.43e-02		6.88e-05
		N	3.19e-02		6.79e-04
	Mother's age at death	Y	3.37e-02		1.78e-04
		N	3.30e-02		1.26e-03
	GrimAge	Y	-8.06e-01		4.37e-02
		N	-1.02e+00		1.20e-02
	Age at menopause onset	Y	2.67e-01		3.08e-04
		N	3.27e-01		5.15e-05

Small Large

B Age at menarche and disease outcomes

Type	Outcome	BMI included	OR (95%CI)		P value
Organ aging	LOAD	Y	0.930 (0.867 to 0.996)		3.87e-02
		N	0.894 (0.800 to 0.998)		4.55e-02
	Osteoporosis	Y	1.009 (1.006 to 1.013)		1.95e-07
		N	1.010 (1.006 to 1.014)		1.19e-07
	Type 2 diabetes	Y	1.096 (1.005 to 1.196)		4.06e-02
		N	1.101 (1.014 to 1.195)		2.37e-02
	CHF	Y	0.953 (0.913 to 0.995)		2.80e-02
		N			1.10e-01
	Essential hypertension	Y	0.966 (0.959 to 0.973)		1.20e-22
		N	0.979 (0.971 to 0.986)		2.54e-08
	Early onset COPD	Y	0.838 (0.755 to 0.931)		9.50e-04
		N	0.846 (0.756 to 0.946)		3.42e-03
Organ cancer	Breast cancer	Y	0.859 (0.764 to 0.966)		1.21e-02
		N	0.942 (0.898 to 0.989)		1.53e-02
	Endometrial cancer	Y	0.896 (0.840 to 0.956)		9.02e-04
		N	0.908 (0.847 to 0.972)		5.92e-03

Lower risk Higher risk

C Age at first birth and disease outcomes

Type	Outcome	BMI included	OR (95%CI)		P value
Organ aging	Type 2 diabetes	Y	0.890 (0.847 to 0.935)		3.65e-06
		N	0.901 (0.853 to 0.951)		1.43e-04
	CHF	Y	0.926 (0.866 to 0.991)		2.56e-02
		N			3.34e-01
	Essential hypertension	Y	0.966 (0.957 to 0.974)		3.45e-15
		N	0.972 (0.963 to 0.981)		4.50e-09
	GAD	Y	0.975 (0.965 to 0.985)		2.02e-06
		N	0.971 (0.961 to 0.982)		9.59e-08
Organ cancer	Cervical cancer	Y	0.978 (0.975 to 0.982)		1.59e-02
		N			6.02e-02

Lower risk

Figure 1. Genetic associations between exposures and outcomes. (**A**), genetic associations between exposures and aging outcomes. Later age at menarche was associated with a lower frailty index and facial aging, higher parental ages at death, and later menopause. Later age at first birth was associated with lower frailty index and GrimAge, higher parental ages at death, and later menopause. (**B**), genetic associations between age at menarche and outcomes of organ diseases. Later age at menarche was associated with lower risks of LOAD, CHF, essential hypertension, early onset COPD, breast cancer, and endometrial cancer. (**C**), genetic associations between age at first birth and outcomes of organ diseases. Later age at first birth was associated with lower risks of type 2 diabetes, CHF, essential hypertension, gastrointestinal or abdominal disease, and cervical cancer. The significant associations were not detected after BMI-related SNPs excluded for outcomes of CHF and cervical cancer. BMI included, BMI-related SNPs included; LOAD, late-onset Alzheimer's disease; CHF, chronic heart failure; COPD, chronic obstructive pulmonary; GAD,

Figure 2. **List and heatmap of SNPs/genes from post-MR analysis showing an association between age at menarche and first birth with three or more aging outcomes.** Genomic region location for each variant is depicted by different characters: intron variant[#]; 2KB upstream variant[$]; Missense variant[*]; Intergenic variant[&]; Regulatory region variant[@]; 3' UTR variant[†]; Synonymous Variant[~]. Heatmap is representative of an association of each gene/SNP with different aging outcomes. Red bar represents a harmful association (-beta for Father's DA, Mother's DA, and menopause; +beta for other outcomes); Blue bar represents a beneficial association (+beta for Father's DA, Mother's DA, and menopause; -beta for other outcomes); White bar represents no association. AFB; age at first birth; FI, frailty index; Father's DA, father's age at death; Mother's DA, mother's age at death; Menopause, age at menopause; LOAD, late-onset Alzheimer's disease; OS, osteoporosis; T2D, type II diabetes; CHF, chronic heart failure; EH, essential hypertension; FA, facial aging; COPD, chronic obstructive pulmonary disease; GAD, gastrointestinal or abdominal disease; BC, breast cancer; EC, endometrial cancer; CC, cervical cancer; BMI, body mass index.

Figure 3. Ingenuity Pathway Analysis (IPA). SNPs/gene outcomes from MR analysis were subjected to IPA. (**A**) Canonical signaling pathways in age at menarche and first birth. The adjusted P-values of the top 25 signaling pathways are listed. (**B**) Disease and functions in age at first birth and menarche. The adjusted P-value of the top 20 significantly involved diseases and functions are listed. (**C**) IPA network 1 and (**D**) IPA network 2. The genes from our post-MR analysis are in bold. Solid lines indicate direct connections, while dotted lines indicate indirect connections (circular arrows mean influence itself). Color coding: pink-receptors, green-enzymes, blue-transcriptional regulators, red-growth factor, orange-other proteins .

Figure 4. The distributions of outcome age and risk according to age group of menarche and fist live birth as well as number of births before and after correcting confounders. Condition Baseline, no confounder was corrected. Conditions Highest education and Lowest education, confounders of education, smoking, and drinking were corrected, and bars were painted based on most smoking and drinking situations with the highest and lowest education levels. Conditions Median education with BMI 18.5-24.9, Median education with BMI 25-29.9, and Median education with BMI 30-, confounders of education, smoking, drinking, and BMI were corrected, and bars were painted based on median education and most smoking and drinking situation with 3 BMI categories. BMI, body mass index; HBP, high blood pressure; COPD, chronic obstructive pulmonary disease; AD, Alzheimer's disease.

References

1. Medawer, P. B. An Unsolved Problem of Biology. (1952).
2. Byars, S. G. & Voskarides, K. Antagonistic Pleiotropy in Human Disease. *J Mol Evol* **88**, 12-25 (2020). https://doi.org:10.1007/s00239-019-09923-2
3. Wang, Z. & Cong, H. Antagonistic pleiotropy can promote adaptation to patchy environments. *Evolution* **75**, 197-199 (2021). https://doi.org:10.1111/evo.14133
4. Kumar, J. *et al.* Zinc Levels Modulate Lifespan through Multiple Longevity Pathways in Caenorhabditis elegans. *PLoS One* **11**, e0153513 (2016). https://doi.org:10.1371/journal.pone.0153513
5. Grundy, E. & Tomassini, C. Fertility history and health in later life: a record linkage study in England and Wales. *Soc Sci Med* **61**, 217-228 (2005). https://doi.org:10.1016/j.socscimed.2004.11.046
6. Day, F. R. *et al.* Physical and neurobehavioral determinants of reproductive onset and success. *Nat Genet* **48**, 617-623 (2016). https://doi.org:10.1038/ng.3551
7. Sanderson, E. *et al.* Mendelian randomization. *Nat Rev Methods Primers* **2** (2022). https://doi.org:10.1038/s43586-021-00092-5
8. Loh, P. R., Kichaev, G., Gazal, S., Schoech, A. P. & Price, A. L. Mixed-model association for biobank-scale datasets. *Nat Genet* **50**, 906-908 (2018). https://doi.org:10.1038/s41588-018-0144-6
9. Mills, M. C. *et al.* Identification of 371 genetic variants for age at first sex and birth linked to externalising behaviour. *Nat Hum Behav* **5**, 1717-1730 (2021). https://doi.org:10.1038/s41562-021-01135-3
10. Ng, J. C. M. & Schooling, C. M. Effect of basal metabolic rate on lifespan: a sex-specific Mendelian randomization study. *Sci Rep* **13**, 7761 (2023). https://doi.org:10.1038/s41598-023-34410-6
11. Williams, D. M., Jylhava, J., Pedersen, N. L. & Hagg, S. A Frailty Index for UK Biobank Participants. *J Gerontol A Biol Sci Med Sci* **74**, 582-587 (2019). https://doi.org:10.1093/gerona/gly094
12. Locke, A. E. *et al.* Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518**, 197-206 (2015). https://doi.org:10.1038/nature14177
13. Silva-Garcia, C. G. *et al.* The CRTC-1 transcriptional domain is required for COMPASS complex-mediated longevity in C. elegans. *Nat Aging* **3**, 1358-1371 (2023). https://doi.org:10.1038/s43587-023-00517-8
14. Mendioroz, M. *et al.* CRTC1 gene is differentially methylated in the human hippocampus in Alzheimer's disease. *Alzheimers Res Ther* **8**, 15 (2016). https://doi.org:10.1186/s13195-016-0183-0
15. Liu, Y. *et al.* CHAC1 as a Novel Contributor of Ferroptosis in Retinal Pigment Epithelial Cells with Oxidative Damage. *Int J Mol Sci* **24** (2023). https://doi.org:10.3390/ijms24021582
16. Li, J. *et al.* CHAC1 inactivation is effective to preserve muscle glutathione but is insufficient to protect against muscle wasting in cachexia. *PLoS One* **18**, e0283806 (2023). https://doi.org:10.1371/journal.pone.0283806
17. Cloos, P. A. & Christgau, S. Post-translational modifications of proteins: implications for aging, antigen recognition, and autoimmunity. *Biogerontology* **5**, 139-158 (2004). https://doi.org:10.1023/B:BGEN.0000031152.31352.8b
18. Udenwobele, D. I. *et al.* Myristoylation: An Important Protein Modification in the Immune Response. *Front Immunol* **8**, 751 (2017). https://doi.org:10.3389/fimmu.2017.00751
19. Hayashi, N. & Titani, K. N-myristoylated proteins, key components in intracellular signal transduction systems enabling rapid and flexible cell responses. *Proc Jpn Acad Ser B Phys Biol Sci* **86**, 494-508 (2010). https://doi.org:10.2183/pjab.86.494
20. Wen, Z. *et al.* N-myristoyltransferase deficiency impairs activation of kinase AMPK and promotes synovial tissue inflammation. *Nat Immunol* **20**, 313-325 (2019). https://doi.org:10.1038/s41590-018-0296-7
21. Liang, J. *et al.* Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance. *Nat Commun* **6**, 7926 (2015). https://doi.org:10.1038/ncomms8926
22. McHugh, D. *et al.* COPI vesicle formation and N-myristoylation are targetable vulnerabilities of senescent cells. *Nat Cell Biol* **25**, 1804-1820 (2023). https://doi.org:10.1038/s41556-023-01287-6
23. Thinon, E., Morales-Sanfrutos, J., Mann, D. J. & Tate, E. W. N-Myristoyltransferase Inhibition Induces ER-Stress, Cell Cycle Arrest, and Apoptosis in Cancer Cells. *ACS Chem Biol* **11**, 2165-2176 (2016). https://doi.org:10.1021/acschembio.6b00371
24. Zhu, G. *et al.* N-Myristoylation by NMT1 Is POTEE-Dependent to Stimulate Liver Tumorigenesis via Differentially Regulating Ubiquitination of Targets. *Front Oncol* **11**, 681366 (2021). https://doi.org:10.3389/fonc.2021.681366
25. Tomita, Y. *et al.* Targeting N-Myristoylation Through NMT2 Prevents Cardiac Hypertrophy and Heart Failure. *JACC Basic Transl Sci* **8**, 1263-1282 (2023). https://doi.org:10.1016/j.jacbts.2023.06.006
26. Ashrafi, K., Lin, S. S., Manchester, J. K. & Gordon, J. I. Sip2p and its partner snf1p kinase affect aging in S. cerevisiae. *Genes Dev* **14**, 1872-1885 (2000).
27. Kramer, A., Green, J., Pollard, J., Jr. & Tugendreich, S. Causal analysis approaches in Ingenuity Pathway Analysis. *Bioinformatics* **30**, 523-530 (2014). https://doi.org:10.1093/bioinformatics/btt703
28. Gaulton, A. *et al.* ChEMBL: a large-scale bioactivity database for drug discovery. *Nucleic Acids Res* **40**, D1100-1107 (2012). https://doi.org:10.1093/nar/gkr777
29. Wishart, D. S. *et al.* DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic Acids Res* **46**, D1074-D1082 (2018). https://doi.org:10.1093/nar/gkx1037

van den Heuvel, J., English, S. & Uller, T. Disposable Soma Theory and the Evolution of Maternal Effects on Ageing. *PLoS One* **11**, e0145544 (2016). https://doi.org:10.1371/journal.pone.0145544

Douglas, P. M. & Dillin, A. The disposable soma theory of aging in reverse. *Cell Res* **24**, 7-8 (2014). https://doi.org:10.1038/cr.2013.148

Guo, H. J., Ye, Y. L., Gao, Y. F. & Liu, Z. H. Age at first birth is associated with the likelihood of frailty in middle-aged and older women: A population-based analysis from NHANES 1999-2018. *Maturitas* **181**, 107904 (2023). https://doi.org:10.1016/j.maturitas.2023.107904

Long, E. & Zhang, J. Evidence for the role of selection for reproductively advantageous alleles in human aging. *Sci Adv* **9**, eadh4990 (2023). https://doi.org:10.1126/sciadv.adh4990

Liu, D. *et al.* Vitamin D and Multiple Health Outcomes: An Umbrella Review of Observational Studies, Randomized Controlled Trials, and Mendelian Randomization Studies. *Adv Nutr* **13**, 1044-1062 (2022). https://doi.org:10.1093/advances/nmab142

Chen, X. *et al.* Kidney damage causally affects the brain cortical structure: A Mendelian randomization study. *EBioMedicine* **72**, 103592 (2021). https://doi.org:10.1016/j.ebiom.2021.103592

Barth, C. & de Lange, A. G. Towards an understanding of women's brain aging: the immunology of pregnancy and menopause. *Front Neuroendocrinol* **58**, 100850 (2020). https://doi.org:10.1016/j.yfrne.2020.100850

Sherwin, B. B. & Henry, J. F. Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: a critical review. *Front Neuroendocrinol* **29**, 88-113 (2008). https://doi.org:10.1016/j.yfrne.2007.08.002

Day, F. R., Elks, C. E., Murray, A., Ong, K. K. & Perry, J. R. Puberty timing associated with diabetes, cardiovascular disease and also diverse health outcomes in men and women: the UK Biobank study. *Sci Rep* **5**, 11208 (2015). https://doi.org:10.1038/srep11208

Hollis, B. *et al.* Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan. *Nat Commun* **11**, 1536 (2020). https://doi.org:10.1038/s41467-020-14451-5

Jorge, S., Chang, S., Barzilai, J. J., Leppert, P. & Segars, J. H. Mechanical signaling in reproductive tissues: mechanisms and importance. *Reprod Sci* **21**, 1093-1107 (2014). https://doi.org:10.1177/1933719114542023

Baumgarten, S. C., Armouti, M., Ko, C. & Stocco, C. IGF1R Expression in Ovarian Granulosa Cells Is Essential for Steroidogenesis, Follicle Survival, and Fertility in Female Mice. *Endocrinology* **158**, 2309-2318 (2017). https://doi.org:10.1210/en.2017-00146

Botkjaer, J. A. *et al.* Dynamics of IGF signalling during the ovulatory peak in women undergoing ovarian stimulation. *J Clin Endocrinol Metab* (2024). https://doi.org:10.1210/clinem/dgae132

Stubbs, S. A. *et al.* Role of Insulin-like growth factors in initiation of follicle growth in normal and polycystic human ovaries. *J Clin Endocrinol Metab* **98**, 3298-3305 (2013). https://doi.org:10.1210/jc.2013-1378

Papaconstantinou, J. Insulin/IGF-1 and ROS signaling pathway cross-talk in aging and longevity determination. *Mol Cell Endocrinol* **299**, 89-100 (2009). https://doi.org:10.1016/j.mce.2008.11.025

Kalman, S. M. Effects of oral contraceptives. *Annu Rev Pharmacol* **9**, 363-378 (1969). https://doi.org:10.1146/annurev.pa.09.040169.002051

van Heemst, D. Insulin, IGF-1 and longevity. *Aging Dis* **1**, 147-157 (2010).

Junnila, R. K., List, E. O., Berryman, D. E., Murrey, J. W. & Kopchick, J. J. The GH/IGF-1 axis in ageing and longevity. *Nat Rev Endocrinol* **9**, 366-376 (2013). https://doi.org:10.1038/nrendo.2013.67

Aleandri, V., Spina, V. & Ciardo, A. [The role of the pineal body in the endocrine control of puberty]. *Minerva Ginecol* **49**, 43-48 (1997).

Olcese, J. M. Melatonin and Female Reproduction: An Expanding Universe. *Front Endocrinol (Lausanne)* **11**, 85 (2020). https://doi.org:10.3389/fendo.2020.00085

Chen, D., Zhao, M. & Mundy, G. R. Bone morphogenetic proteins. *Growth Factors* **22**, 233-241 (2004). https://doi.org:10.1080/08977190412331279890

Magro-Lopez, E. & Munoz-Fernandez, M. A. The Role of BMP Signaling in Female Reproductive System Development and Function. *Int J Mol Sci* **22** (2021). https://doi.org:10.3390/ijms222111927

Childs, A. J. *et al.* BMP signaling in the human fetal ovary is developmentally regulated and promotes primordial germ cell apoptosis. *Stem Cells* **28**, 1368-1378 (2010). https://doi.org:10.1002/stem.440

da Cunha, E. V. *et al.* Effects of bone morphogenetic protein 4 (BMP4) on in vitro development and survival of bovine preantral follicles enclosed in fragments ovarian tissue. *Zygote* **25**, 256-264 (2017). https://doi.org:10.1017/S0967199417000089

Zhang, X. *et al.* BMP4 overexpression induces the upregulation of APP/Tau and memory deficits in Alzheimer's disease. *Cell Death Discov* **7**, 51 (2021). https://doi.org:10.1038/s41420-021-00435-x

Meyers, E. A. *et al.* Increased bone morphogenetic protein signaling contributes to age-related declines in neurogenesis and cognition. *Neurobiol Aging* **38**, 164-175 (2016). https://doi.org:10.1016/j.neurobiolaging.2015.10.035

Ye, D. *et al.* Insights into bone morphogenetic proteins in cardiovascular diseases. *Front Pharmacol* **14**, 1125642 (2023). https://doi.org:10.3389/fphar.2023.1125642

Baboota, R. K., Bluher, M. & Smith, U. Emerging Role of Bone Morphogenetic Protein 4 in Metabolic Disorders. *Diabetes* **70**, 303-312 (2021). https://doi.org:10.2337/db20-0884

Saenger, P. Dose effects of growth hormone during puberty. *Horm Res* **60**, 52-57 (2003). https://doi.org:10.1159/000071226

Bartke, A. Growth hormone and aging. *Rev Endocr Metab Disord* **22**, 71-80 (2021). https://doi.org:10.1007/s11154-020-09593-2

Fulop, T., Larbi, A. & Pawelec, G. Human T cell aging and the impact of persistent viral infections. *Front Immunol* **4**, 271 (2013). https://doi.org:10.3389/fimmu.2013.00271

Franceschi, C. & Campisi, J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. *J Gerontol A Biol Sci Med Sci* **69 Suppl 1**, S4-9 (2014). https://doi.org:10.1093/gerona/glu057

Vilchez, D., Saez, I. & Dillin, A. The role of protein clearance mechanisms in organismal ageing and age-related diseases. *Nat Commun* **5**, 5659 (2014). https://doi.org:10.1038/ncomms6659

Benayoun, B. A., Pollina, E. A. & Brunet, A. Epigenetic regulation of ageing: linking environmental inputs to genomic stability. *Nat Rev Mol Cell Biol* **16**, 593-610 (2015). https://doi.org:10.1038/nrm4048

Ciechanover, A. & Kwon, Y. T. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. *Exp Mol Med* **47**, e147 (2015). https://doi.org:10.1038/emm.2014.117

Austad, S. N. & Hoffman, J. M. Is antagonistic pleiotropy ubiquitous in aging biology? *Evol Med Public Health* **2018**, 287-294 (2018). https://doi.org:10.1093/emph/eoy033

Kalous, J., Aleshkina, D. & Anger, M. A Role of PI3K/Akt Signaling in Oocyte Maturation and Early Embryo Development. *Cells* **12** (2023). https://doi.org:10.3390/cells12141830

Chung, E., Yeung, F. & Leinwand, L. A. Akt and MAPK signaling mediate pregnancy-induced cardiac adaptation. *J Appl Physiol (1985)* **112**, 1564-1575 (2012). https://doi.org:10.1152/japplphysiol.00027.2012

Chen, Y. R. *et al.* Aging-induced Akt activation involves in aging-related pathologies and Abeta-induced toxicity. *Aging Cell* **18**, e12989 (2019). https://doi.org:10.1111/acel.12989

Howard, S. R. Interpretation of reproductive hormones before, during and after the pubertal transition-Identifying health and disordered puberty. *Clin Endocrinol (Oxf)* **95**, 702-715 (2021). https://doi.org:10.1111/cen.14578

Bhartiya, D., Sriraman, K., Gunjal, P. & Modak, H. Gonadotropin treatment augments postnatal oogenesis and primordial follicle assembly in adult mouse ovaries? *J Ovarian Res* **5**, 32 (2012). https://doi.org:10.1186/1757-2215-5-32

Danilovich, N., Javeshghani, D., Xing, W. & Sairam, M. R. Endocrine alterations and signaling changes associated with declining ovarian function and advanced biological aging in follicle-stimulating hormone receptor haploinsufficient mice. *Biol Reprod* **67**, 370-378 (2002). https://doi.org:10.1095/biolreprod67.2.370

Hale, G. E. *et al.* Endocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) staging system. *J Clin Endocrinol Metab* **92**, 3060-3067 (2007). https://doi.org:10.1210/jc.2007-0066

Santoro, N. & Randolph, J. F., Jr. Reproductive hormones and the menopause transition. *Obstet Gynecol Clin North Am* **38**, 455-466 (2011). https://doi.org:10.1016/j.ogc.2011.05.004

Vanden Brink, H. *et al.* Associations Between Antral Ovarian Follicle Dynamics and Hormone Production Throughout the Menstrual Cycle as Women Age. *J Clin Endocrinol Metab* **100**, 4553-4562 (2015). https://doi.org:10.1210/jc.2015-2643

Abdellatif, M. *et al.* Fine-Tuning Cardiac Insulin-Like Growth Factor 1 Receptor Signaling to Promote Health and Longevity. *Circulation* **145**, 1853-1866 (2022). https://doi.org:10.1161/CIRCULATIONAHA.122.059863

Lundgren, S. *et al.* BMI is positively associated with accelerated epigenetic aging in twin pairs discordant for body mass index. *J Intern Med* **292**, 627-640 (2022). https://doi.org:10.1111/joim.13528

Quach, A. *et al.* Epigenetic clock analysis of diet, exercise, education, and lifestyle factors. *Aging (Albany NY)* **9**, 419-446 (2017). https://doi.org:10.18632/aging.101168

Wilson, K. A. *et al.* Evaluating the beneficial effects of dietary restrictions: A framework for precision nutrigeroscience. *Cell Metab* **33**, 2142-2173 (2021). https://doi.org:10.1016/j.cmet.2021.08.018

Balasch, J. Ageing and infertility: an overview. *Gynecol Endocrinol* **26**, 855-860 (2010). https://doi.org:10.3109/09513590.2010.501889

Atkins, J. L. *et al.* A genome-wide association study of the frailty index highlights brain pathways in ageing. *Aging Cell* **20**, e13459 (2021). https://doi.org:10.1111/acel.13459

Pilling, L. C. *et al.* Human longevity: 25 genetic loci associated in 389,166 UK biobank participants. *Aging (Albany NY)* **9**, 2504-2520 (2017). https://doi.org:10.18632/aging.101334

McCartney, D. L. *et al.* Genome-wide association studies identify 137 genetic loci for DNA methylation biomarkers of aging. *Genome Biol* **22**, 194 (2021). https://doi.org:10.1186/s13059-021-02398-9

Kunkle, B. W. *et al.* Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. *Nat Genet* **51**, 414-430 (2019). https://doi.org:10.1038/s41588-019-0358-2

Donertas, H. M., Fabian, D. K., Valenzuela, M. F., Partridge, L. & Thornton, J. M. Common genetic associations between age-related diseases. *Nat Aging* **1**, 400-412 (2021). https://doi.org:10.1038/s43587-021-00051-5

Sakaue, S. *et al.* A cross-population atlas of genetic associations for 220 human phenotypes. *Nat Genet* **53**, 1415-1424 (2021). https://doi.org:10.1038/s41588-021-00931-x

Ahadi, S. *et al.* Longitudinal fundus imaging and its genome-wide association analysis provide evidence for a human retinal aging clock. *Elife* **12** (2023). https://doi.org:10.7554/eLife.82364

Wojcik, G. L. *et al.* Genetic analyses of diverse populations improves discovery for complex traits. *Nature* **570**, 514-518 (2019). https://doi.org:10.1038/s41586-019-1310-4

O'Mara, T. A. *et al.* Identification of nine new susceptibility loci for endometrial cancer. *Nat Commun* **9**, 3166 (2018). https://doi.org:10.1038/s41467-018-05427-7

Savage, J. E. *et al.* Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. *Nat Genet* **50**, 912-919 (2018). https://doi.org:10.1038/s41588-018-0152-6

Gao, X. *et al.* The bidirectional causal relationships of insomnia with five major psychiatric disorders: A Mendelian randomization study. *Eur Psychiatry* **60**, 79-85 (2019). https://doi.org:10.1016/j.eurpsy.2019.05.004

Staley, J. R. *et al.* PhenoScanner: a database of human genotype-phenotype associations. *Bioinformatics* **32**, 3207-3209 (2016). https://doi.org:10.1093/bioinformatics/btw373

Kamat, M. A. *et al.* PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. *Bioinformatics* **35**, 4851-4853 (2019). https://doi.org:10.1093/bioinformatics/btz469

Burgess, S., Small, D. S. & Thompson, S. G. A review of instrumental variable estimators for Mendelian randomization. *Stat Methods Med Res* **26**, 2333-2355 (2017). https://doi.org:10.1177/0962280215597579

Venkateswaran, S. *et al.* Enhanced Contribution of HLA in Pediatric Onset Ulcerative Colitis. *Inflamm Bowel Dis* **24**, 829-838 (2018). https://doi.org:10.1093/ibd/izx084

Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat Genet* **47**, 1236-1241 (2015). https://doi.org:10.1038/ng.3406

Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* **47**, 291-295 (2015). https://doi.org:10.1038/ng.3211

Wallace, C. A more accurate method for colocalisation analysis allowing for multiple causal variants. *PLoS Genet* **17**, e1009440 (2021). https://doi.org:10.1371/journal.pgen.1009440

Ghosh, S. *et al.* Core Canonical Pathways Involved in Developing Human Glioblastoma Multiforme (GBM). *Int J Sci Res Sci Eng Technol* **3**, 458-465 (2017).